FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to cardiology, and can be used to predict the risk of adverse cardiovascular events within 12 months after coronary bypass surgery. Blood serum of the patients with ischemic heart disease scheduled for coronary artery bypass surgery is examined for the concentration of growth/differentiation factor 15 (GDF-15), pg/ml, and the ratio of neutrophils to blood lymphocytes (NEUT/LYMPH). Risk of adverse cardiovascular events is calculated by formula: p = GDF-15 × (NEUT/LYMPH), where p is the probability of adverse cardiovascular events within 12 months after coronary bypass surgery. If the p value is 3,216 and more, a high risk of unfavourable cardiovascular events is predicted.
EFFECT: method enables predicting the risk of adverse cardiovascular events for 12 months after coronary artery bypass grafting by measuring blood serum of patients with coronary artery disease planned for coronary artery bypass grafting, concentration of GDF-15 and ratio of neutrophils to blood lymphocytes.
1 cl, 2 tbl, 3 ex
